The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Mad2-induced chromosome instability leads to lung tumour relapse after oncogene withdrawal
Open accessAbstract
Inhibition of an initiating oncogene often leads to extensive tumour cell death, a phenomenon known as oncogene addiction. This has led to the search for compounds that specifically target and inhibit oncogenes as anticancer agents. However, there has been no systematic exploration of whether chromosomal instability generated as a result of deregulation of the mitotic checkpoint pathway, a frequent characteristic of solid tumours, has any effect on oncogene addiction. Here we show that induction of chromosome instability by overexpression of the mitotic checkpoint gene Mad2 in mice does not affect the regression of Kras-driven lung tumours when Kras is inhibited. However, tumours that experience transient Mad2 overexpression and consequent chromosome instability recur at markedly elevated rates. The recurrent tumours are highly aneuploid and have varied activation of pro-proliferative pathways. Thus, early chromosomal instability may be responsible for tumour relapse after seemingly effective anticancer treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy
Hochhaus, A., Kreil, S., Corbin, A., La Rosée, P., Müller, M., Lahaye, T., Hanfstein, B., Schoch, C., Cross, N., Berger, U., et al. (2002) · Leukemia · doi:10.1038/sj.leu.2402741 · Cited by 906
Reversible Tumorigenesis by MYC in Hematopoietic Lineages
Felsher, D. W., & Bishop, J. M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80367-6 · Cited by 881
Essential role for oncogenic Ras in tumour maintenance
Chin, L., Tam, A., Pomerantz, J., Wong, M., Holash, J., Bardeesy, N., Shen, Q., O'Hagan, R., Pantginis, J., Zhou, H., et al. (1999) · Nature · doi:10.1038/22788 · Cited by 875
Aneuploidy Acts Both Oncogenically and as a Tumor Suppressor
Weaver, B. A. A., Silk, A. D., Montagna, C., Verdier-Pinard, P., & Cleveland, D. W. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.12.003 · Cited by 729
Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy
Weinstein, I. B., & Joe, A. K. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0558 · Cited by 705
Mechanisms to suppress multipolar divisions in cancer cells with extra centrosomes
Kwon, M., Godinho, S. A., Chandhok, N. S., Ganem, N. J., Azioune, A., Thery, M., & Pellman, D. (2008) · Genes & Development · doi:10.1101/gad.1700908 · Cited by 651
Cited by
The causes and consequences of genetic heterogeneity in cancer evolution
Burrell, R. A., McGranahan, N., Bartek, J., & Swanton, C. (2013) · Nature · doi:10.1038/nature12625 · Cited by 2,262
Davoli, T., Uno, H., Wooten, E. C., & Elledge, S. J. (2017) · Science · doi:10.1126/science.aaf8399 · Cited by 1,360
Spatial and temporal diversity in genomic instability processes defines lung cancer evolution
de Bruin, E. C., McGranahan, N., Mitter, R., Salm, M., Wedge, D. C., Yates, L., Jamal-Hanjani, M., Shafi, S., Murugaesu, N., Rowan, A. J., et al. (2014) · Science · doi:10.1126/science.1253462 · Cited by 1,117
Causes and consequences of aneuploidy in cancer
Gordon, D. J., Resio, B., & Pellman, D. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3123 · Cited by 815
The broken cycle: E2F dysfunction in cancer
Kent, L. N., & Leone, G. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0143-7 · Cited by 800
The Multifaceted Role of Chromosomal Instability in Cancer and Its Microenvironment
Bakhoum, S. F., & Cantley, L. C. (2018) · Cell · doi:10.1016/j.cell.2018.08.027 · Cited by 717
Context is everything: aneuploidy in cancer
Ben-David, U., & Amon, A. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-019-0171-x · Cited by 665
Resolving genetic heterogeneity in cancer
Turajlic, S., Sottoriva, A., Graham, T., & Swanton, C. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-019-0114-6 · Cited by 653
Short- and long-term effects of chromosome mis-segregation and aneuploidy
Santaguida, S., & Amon, A. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm4025 · Cited by 549
APOBEC Enzymes: Mutagenic Fuel for Cancer Evolution and Heterogeneity
Swanton, C., McGranahan, N., Starrett, G. J., & Harris, R. S. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0344 · Cited by 488
Chromosomal Instability Confers Intrinsic Multidrug Resistance
Lee, A. J. X., Endesfelder, D., Rowan, A. J., Walther, A., Birkbak, N. J., Futreal, P. A., Downward, J., Szallasi, Z., Tomlinson, I. P. M., Howell, M., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3604 · Cited by 475
RB1: a prototype tumor suppressor and an enigma
Dyson, N. J. (2016) · Genes & Development · doi:10.1101/gad.282145.116 · Cited by 435
How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine
Gerlinger, M., & Swanton, C. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605912 · Cited by 421
Mitotic chromosomal instability and cancer: mouse modelling of the human disease
Schvartzman, J.-M., Sotillo, R., & Benezra, R. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2781 · Cited by 414
Self-citationDeterminants and clinical implications of chromosomal instability in cancer
Sansregret, L., Vanhaesebroeck, B., & Swanton, C. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.198 · Cited by 396
Evolutionary Determinants of Cancer
Greaves, M. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0439 · Cited by 395
McGranahan, N., Burrell, R. A., Endesfelder, D., Novelli, M. R., & Swanton, C. (2012) · EMBO reports · doi:10.1038/embor.2012.61 · Cited by 382
Aneuploidy renders cancer cells vulnerable to mitotic checkpoint inhibition
Cohen-Sharir, Y., McFarland, J. M., Abdusamad, M., Marquis, C., Bernhard, S. V., Kazachkova, M., Tang, H., Ippolito, M. R., Laue, K., Zerbib, J., et al. (2021) · Nature · doi:10.1038/s41586-020-03114-6 · Cited by 290
Transcriptional consequences of aneuploidy
Sheltzer, J. M., Torres, E. M., Dunham, M. J., & Amon, A. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1209227109 · Cited by 289
Holland, A. J., & Cleveland, D. W. (2012) · EMBO reports · doi:10.1038/embor.2012.55 · Cited by 288
The impact of mitotic errors on cell proliferation and tumorigenesis
Levine, M. S., & Holland, A. J. (2018) · Genes & Development · doi:10.1101/gad.314351.118 · Cited by 274
The Role of Aneuploidy in Cancer Evolution
Sansregret, L., & Swanton, C. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a028373 · Cited by 266
Chromosomal instability and cancer: a complex relationship with therapeutic potential
Bakhoum, S. F., & Compton, D. A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59954 · Cited by 255
Single-chromosome Gains Commonly Function as Tumor Suppressors
Sheltzer, J. M., Ko, J. H., Replogle, J. M., Habibe Burgos, N. C., Chung, E. S., Meehl, C. M., Sayles, N. M., Passerini, V., Storchova, Z., & Amon, A. (2017) · Cancer Cell · doi:10.1016/j.ccell.2016.12.004 · Cited by 201
Oncogenic Kras drives invasion and maintains metastases in colorectal cancer
Boutin, A. T., Liao, W.-T., Wang, M., Hwang, S. S., Karpinets, T. V., Cheung, H., Chu, G. C., Jiang, S., Hu, J., Chang, K., et al. (2017) · Genes & Development · doi:10.1101/gad.293449.116 · Cited by 195
Schvartzman, J.-M., Duijf, P. H. G., Sotillo, R., Coker, C., & Benezra, R. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.04.017 · Cited by 181
“We have recently shown that Mad2 overexpression and CIN in a KrasG12D-driven model of lung tumorigenesis promotes tumor recurrence after oncogene withdrawal (Sotillo et al., 2010).”
InfluentialSelf-citationEischen, C. M. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026096 · Cited by 161
Rowald, K., Mantovan, M., Passos, J., Buccitelli, C., Mardin, B. R., Korbel, J. O., Jechlinger, M., & Sotillo, R. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.05.048 · Cited by 84
“In addition, Mad2 overexpression in a transgenic model of KrasG12D-driven lung carcinogenesis facilitated both tumor onset and relapse following oncogene silencing (Sotillo et al., 2010).”
BackgroundInfluentialSelf-citationTargeting KRAS Mutant Lung Cancer Cells with siRNA-Loaded Bovine Serum Albumin Nanoparticles
Mehta, A., Dalle Vedove, E., Isert, L., & Merkel, O. M. (2019) · Pharmaceutical Research · doi:10.1007/s11095-019-2665-9 · Cited by 53
Karyotypic Aberrations in Oncogenesis and Cancer Therapy
Vitale, I., Manic, G., Senovilla, L., Kroemer, G., & Galluzzi, L. (2015) · Trends in Cancer · doi:10.1016/j.trecan.2015.08.001 · Cited by 34
Metadata
- Authors
- Sotillo, R., Schvartzman, J.-M., Socci, N. D., & Benezra, R.
- Venue
- Nature
- Published
- 2010-02-21
- Volume
- 464
- Issue
- 7287
- Pages
- 436-440
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1987369248
- Cited by
- 273
- References
- 28
- FWCI
- 9.62
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.